BerGenBio ASA (BRRGF) has released an update.
BerGenBio ASA reported substantial clinical and financial advancements, including the completion of enrollment for the Ph1b part of their BGBC016 study and initiation of the second dose in the Ph2a part, for treating STK11 mutated NSCLC. They have also established a data collaboration with Tempus AI to potentially expedite the development of their lead candidate, bemcentinib. Financially, the company has secured NOK 138.9 million in funding, ensuring operations into the second half of 2025, with a stable cash reserve of NOK 200.1 million as of Q2 2024.
For further insights into BRRGF stock, check out TipRanks’ Stock Analysis page.
